30.36

2.06% -0.64

Q 32 Bio Inc (QTTB)

Overview News Price History Discussions Forecast

Q 32 Bio Inc stock is currently priced at $30.36, with a 24-hour trading volume of 62,605. It has seen a -2.06% decreased in the last 24 hours and a +25.87% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $31.21 pivot point. If it approaches the $29.55 support level, significant changes may occur.

Previous Close:

$31.00

Open:

$31

24h Volume:

62,605

Market Cap:

$362.56M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+11.91%

1M Performance:

+25.87%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$29.56

$32.21

52W Range:

$21.28

$32.88

Q 32 Bio Inc Stock (QTTB) Company Profile

Name

Q 32 Bio Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

781-301-7277

Address

ONE PATRIOTS PARK, BEDFORD

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

QTTB's Discussions on Twitter

Q 32 Bio Inc Stock (QTTB) Latest News

Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 - Yahoo New Zealand News

Yahoo New Zealand News

Q32 Bio Inc. Faces New Financial Hurdles as Increased Regulatory Compliance Looms - TipRanks.com - TipRanks

TipRanks

Q32 Bio: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

PR Newswire

Q32 Bio: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Q32 Bio (NASDAQ:QTTB) Trading Down 2.9% - MarketBeat

MarketBeat

Q 32 Bio Inc Stock (QTTB) Financials Data

There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.

Q 32 Bio Inc Stock (QTTB) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Michaud Charles Jr	See Remarks	Mar 25 '24	Sale	24.20	75	1,815	927
TZIANABOS ARTHUR	Director	Jan 09 '24	Sale	0.57	13,037	7,445	128,778
Alloway Paul	See Remarks	Jan 03 '24	Sale	0.57	7,280	4,120	28,036
Michaud Charles Jr	See Remarks	Jan 03 '24	Sale	0.57	1,708	975	11,598
Seymour Albert	See Remarks	Sep 06 '23	Sale	1.15	1,448	1,665	150,874
Jordan Julie	Chief Medical Officer	Aug 03 '23	Option Exercise	0.00	6,579	0	8,804
Jordan Julie	Chief Medical Officer	Aug 03 '23	Sale	1.39	1,853	2,576	3,882
Jordan Julie	Chief Medical Officer	Aug 02 '23	Option Exercise	0.00	350	0	2,869
Jordan Julie	Chief Medical Officer	Aug 02 '23	Sale	1.31	99	130	2,770

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.